AMPER LINDA E 4
4 · OSI PHARMACEUTICALS INC · Filed Mar 3, 2010
Insider Transaction Report
Form 4
AMPER LINDA E
Sr. VP, Human Resources
Transactions
- Exercise/Conversion
Common Stock
2010-03-01$23.83/sh+8,499$202,531→ 34,970 total - Sale
Common Stock
2010-03-01$55.20/sh−15,869$875,969→ 19,101 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-01−7,370→ 0 totalExercise: $38.01From: 2006-06-15Exp: 2012-06-14→ Common Stock (7,370 underlying) - Exercise/Conversion
Common Stock
2010-03-01$38.01/sh+7,370$280,134→ 26,471 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-01−8,499→ 3,001 totalExercise: $23.83From: 2006-12-01Exp: 2012-11-30→ Common Stock (8,499 underlying)
Footnotes (5)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2008.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.39 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Stock option was accelerated on November 30, 2005 pursuant to the decision of the Compensation Committee of the Board of Directors to accelerate the vesting of all out-of-the-money stock options with an exercise price greater than $30 for all employees other than then-current executive officers.
- [F4]25% of the stock options became exerciseable one year after the date of grant and the remainder vested ratably on a monthly basis over the succeeding 36 months.
- [F5]Includes only options with the same termination date.